We described here our results on the use of thiourea as a ligand in the copper catalysed azide‐alkyne cycloaddition (CuAAC) of 2‐azidobenzaldehyde with alkynes. Reactions were performed reacting 2‐azidobenzaldehyde with a range of terminal alkynes using 10 mol % of copper iodide as a catalyst, 20 mol % of thiourea as a ligand, triethylamine as base, DMSO as solvent at 100 °C under nitrogen atmosphere. The corresponding 2‐(1H‐1,2,3‐triazoyl)‐benzaldehydes (2‐TBH) were obtained in moderated to excellent yields and according our experiments, the use of thiourea decreases the formation of side products. The obtained compounds were screened for their binding affinity with multiple therapeutic targets of AD by molecular docking: β‐secretase (BACE), glycogen synthase kinase (GSK‐3β) and acetylcholinesterase (AChE). The three compounds with highest affinity, 5 a (2‐(4‐phenyl‐1H‐1,2,3‐triazol‐1‐yl)benzaldehyde), 5 b (2‐(4‐(p‐tolyl)‐1H‐1,2,3‐triazol‐1‐yl)benzaldehyde), and 5 d (2‐(4‐(4‐(tert‐butyl)phenyl)‐1H‐1,2,3‐triazol‐1‐yl)benzaldehyde) were selected and evaluated on its antioxidant effect, in view of select the most promising one to perform the in vivo validation. Due the antioxidant potential ally to the affinity with BACE, GSK‐3β and AChE, compound 5 b was evaluated in a mouse model of AD induced by intracerebroventricular injection of streptozotocin (STZ). Our results indicate that 5 b (1 mg/kg) treatment during 20 days is able to reverse the cognitive and memory impairment induced by STZ trough the modulation of AChE activity, amyloid cascade and GSK‐3β expression.
We describe our results for the synthesis of 2′-(1,2,3-triazoyl)-acetophenones by copper catalyzed azide–alkyne cycloaddition of 2′-azidoacetophenone with alkynes. The corresponding 2′-(1,2,3-triazoyl)-acetophenones were obtained in moderate to excellent yields and according to our experiments, it was observed that ultrasound accelerates the reaction compared to conventional heating. In addition, the obtained compounds were screened by molecular docking for their possible inhibitory effect on the activity of monoamine oxidase (MAO), an enzyme responsible for the degradation of monoamine neurotransmitters. Three compounds were selected and presented an inhibitory effect on both MAO-A and B isoform activities in vitro. These new MAO inhibitors may be of interest to treat monoamine deficit related-neuropsychiatric disorders, such as depression and Parkinson's disease.